BECTON DICKINSON & CO News
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
see moreBECTON DICKINSON & CO Market News
4d
BDX Stock Faces Pressure Amid Analyst Downgrades and Market Volatility
- BDX stock declines due to analyst downgrades and market volatility.
10d
BDX Stock Declines Amid Analyst Downgrade and Market Volatility
BDX shares fall following analyst downgrade and market shifts.
25 May at 04:09
BDX: Elyra TFL Launch and €600M Debt Deal Updates!
Becton Dickinson this week rolled out the Elyra thulium fiber laser for urology while issuing €600M of notes to refinance near-term debt. Both moves—one clinical, one capital—have clear, measurable implications for execution, revenue trajectory, and balance-sheet flexibility.
18 May at 04:09
BDX Q2 Beat; CentroVena Launch; FDA Ship Hold +$2B
Becton, Dickinson & Company (BDX) posted a solid Q2 with an EPS beat, raised guidance, and executed heavy capital returns while launching the BD CentroVena One insertion system and expanding AI-enabled medication management. A voluntary FDA ship hold on antiseptic products from an El Paso plant introduces a short-term operational risk investors should monitor.
04 May at 04:09
BDX Upside: HemoSphere Launch vs Argus Cut Impacts
This article summarizes last week's concrete developments for Becton, Dickinson (BDX): the HemoSphere Stream launch, an AI medication-dispensing rollout in Europe, an Argus price-target cut, and HIRC supply-chain awards — and explains how each item could affect near-term revenue, margins, and investor sentiment.
27 Apr at 04:09
BDX: Implant Trials, Revenue Miss, Volume Jump Q2.
Becton Dickinson (BDX) saw a sharp rise in trading volume after a mixed earnings release: a modest EPS beat but a revenue shortfall, plus narrowed guidance and analyst downgrades. Concurrently, roughly 2,765 implantable-port liability claims consolidated in an MDL have trial dates this spring and summer, adding near-term legal risk that investors are watching closely.
20 Apr at 04:09
BDX Reshapes Focus After Spin-Off, $1.6B Tender Up
Becton, Dickinson refocused after spinning off its Biosciences & Diagnostics unit into a merger with Waters, returned about $4B in proceeds, launched a $1.6B debt tender and trimmed fiscal 2026 guidance. These concrete capital-allocation moves and the guidance reset remain the primary drivers for BDX stock.